

Proj. Ref. No. BAC1-2022-08-0051-B

End-User Property and Supply Division

Project Supply and Delivery of Drugs and Medicines - Tablet/Oral Solids

Opening of Bids: 16 September 2022

ITEM NO.	QTY	UNIT	ITEM DESCRIPTION	ABC PER UNIT (PHP)	QUOTATIONS (all taxes included)	
					in figures	in words
			<b>TABLETS/ORAL SOLID</b>			
1	9,040	piece	Aciclovir 400mg tablet	30.00		
2	1,200	piece	Aripiprazole 10mg tablet	62.45		
3	45,541	piece	Aspirin 80mg enteric coated tablet	2.10		
4	17,514	piece	Atorvastatin calcium 10mg tablet	7.88		
5	23,939	piece	Atorvastatin calcium 20mg tablet	4.20		
6	47,730	piece	Atorvastatin calcium 40mg tablet	9.45		
7	22,610	piece	Atorvastatin calcium 80mg tablet	8.93		
8	540	piece	Betahistine (as hydrochloride/dihydrochloride) 8mg tablet	12.60		
9	8,060	piece	Carbamazepine 200mg tablet	4.26		
10	32,661	piece	Carvedilol 25mg tablet	5.25		
11	1,856	piece	Cefixime 200mg capsule	8.40		
12	19,114	piece	Cefuroxime axetil 500mg tablet	9.98		
13	2,600	piece	Celecoxib 100mg capsule	2.10		
14	8,773	piece	Cetirizine di-Hydrochloride 10mg tablet	3.59		
15	2,440	piece	Clindamycin Hydrochloride 150mg capsule	6.80		
16	9,427	piece	Clonidine Hydrochloride 75mcg tablet	9.56		
17	36,769	piece	Clopidogrel 75mg tablet	6.04		
18	28,142	piece	Clozapine 100mg tablet	30.45		
19	7,110	piece	Co-Amoxiclav (amoxicillin + potassium clavulanate) 875 mg amoxicillin (as trihydrate) + 125 mg potassium clavulanate per tablet	7.19		
20	5,160	piece	Eperisone Hydrochloride 50mg tablet	29.00		
21	30,340	piece	Ferrous/folic acid 60 mg elemental iron/400 mcg per tablet/capsule/film coated tablet	1.88		
22	38,550	piece	Folic acid 5mg tablet/capsule	4.20		
23	16,720	piece	Isoniazid + Rifampicin 75 mg + 150 mg tablet	9.45		
24	10,165	piece	Isosorbide-5-mononitrate 30mg MR tablet/capsule	6.83		
25	5,590	piece	Isosorbide-5-mononitrate 60mg MR tablet/capsule	12.00		
26	2,165	piece	Lamotrigine 50mg tablet	5.64		
27	582	piece	Lamotrigine 100mg tablet	15.75		
28	7,240	piece	Levofloxacin 500mg tablet	7.35		
29	7,937	piece	Levofloxacin 750mg tablet	12.60		
30	3,040	piece	Levothyroxine (as sodium/anhydrous sodium) 150mcg tablet	10.89		
31	5,637	piece	Loratadine 10mg tablet/film-coated tablet	1.41		
32	9,941	piece	Mefenamic acid 500mg tablet/capsule	11.55		
33	60,002	piece	Mercaptopurine 50mg tablet	25.00		
34	90,258	piece	Metformin Hydrochloride 500mg tablet/film-coated tablet	0.51		
35	31,080	piece	Methotrexate (as base or sodium salt) 2.5mg tablet	4.72		
36	8,619	piece	Metoclopramide Hydrochloride 10mg tablet	6.30		
37	5,635	piece	Metoprolol tartrate 100mg tablet	2.10		
38	18,905	piece	Metoprolol tartrate 50mg tablet	1.05		
39	20,337	piece	Omeprazole 20mg capsule	2.24		
40	26,520	piece	Potassium Chloride 600 mg tablet	18.00		
41	27,049	piece	Potassium citrate 10mEq tablet	7.35		
42	28,053	piece	Prednisone 10mg tablet	4.40		
43	5,983	piece	Quetiapine (as fumarate) 100mg tablet	88.88		
44	9,226	piece	Quetiapine (as fumarate) 25mg tablet	12.60		
45	5,047	piece	Quetiapine (as fumarate) 200mg tablet	70.00		
46	5,700	piece	Ranitidine Hydrochloride 300mg tablet	3.80		
47	6,592	piece	Rifaximin 200mg tablet	66.36		
48	8,010	piece	Risperidone 1mg tablet	10.89		

Proj. Ref. No. BAC1-2022-08-0051-B

End-User Property and Supply Division

Project Supply and Delivery of Drugs and Medicines - Tablet/Oral Solids

Opening of Bids: **16 September 2022**

49	19,091	piece	Risperidone 2mg tablet	40.95		
50	10,745	piece	Rosuvastatin calcium 10mg tablet	12.81		
51	14,910	piece	Rosuvastatin calcium 20mg tablet	22.05		
52	14,423	piece	Sodium Valproate + Valproic Acid 500 mg (333 mg sodium valproate + 145 mg valproic acid) controlled release tablet	11.95		
53	48,102	piece	Tamoxifen citrate 20mg tablet	2.15		
54	16,695	piece	Tamsulosin 400mcg prolonged release film-coated tablet	98.87		
55	2,960	piece	Tamsulosin Hydrochloride 200mcg capsule	28.00		
56	23,316	piece	Telmisartan 40mg tablet	16.87		
57	28,087	piece	Telmisartan 80mg tablet	28.13		
58	2,170	piece	Tenofovir disoproxil fumarate 300 mg tablet	41.22		
59	1,810	piece	Tenofovir alafenamide fumarate 25 mg tablet	70.00		
60	2,312	piece	Topiramate 25mg tablet	26.00		
61	24,360	piece	Tramadol Hydrochloride 50mg capsule/dispersible tablet	7.35		
62	26,792	piece	Trimetazidine Hydrochloride 35mg tablet	11.55		
63	1,620	piece	Ursodeoxycholic acid 250mg capsule	28.35		
64	700	piece	Valaciclovir (as hydrochloride) 500mg tablet	252.00		
65	1,050	piece	Valsartan 80mg tablet/film-coated tablet	11.23		
66	73,879	piece	Vitamin B1 100 mg + B6 5 mg + B12 50 microgram per tablet/capsule	4.20		
<b>TOTAL APPROVED BUDGET FOR THE CONTRACT: PhP13,941,239.76</b>						

Approved by:

Dean CHARLOTTE M. CHIONG, MD, PhD  
Chairperson

\_\_\_\_\_  
(Signature over Printed Name of President/Gen. Manager)

\_\_\_\_\_  
(Name & Address of Company)

**TERMS AND CONDITIONS**

1. Indicate the **brand and packing of the item/s** offered.
  2. The brand offered must be **at least five (5) years commercially available in the market from date of opening of bids**. Proof of this shall be the initial Certificate of Product Registration (CPR) issued by the Food and Drug Administration (FDA).
  3. **Submit the following documents, submission should be per product, with tab and per item number. Two (2) copies for the Valid Certificate of Product Registration and Certificate of Analysis (COA).**
    - 3.1. **Memorandum of Agreement (MOA) and Certificate of exclusive/authorized distributorship between the manufacturer and distributor/suppliers must have certification from their principals that they are the exclusive distributor of the drug products authorized to tender for the product on behalf of the principal and that all commitments made by them shall be honored by the principal in case of termination of distributorship agreement.**
    - 3.2. **Valid Certificate of Product Registration (CPR) issued by the Food and Drug Administration (FDA).**
      - The name of the respective distributor should appear on the submitted CPR of the drug.
- Note: CPRs that will expire within three (3) months from the date of opening of bids should present the Official Receipt of renewal of application and Document Tracking log for the CPR from the FDA.**
- 3.3. **Certificate of Analysis (COA) for the products offered (batch to be delivered if awarded) duly issued by an FDA-accredited laboratory (local or foreign) and should contain information indicated in monograph of the drug. Sample analyzed must not be expired during the time of bidding. The result of assay submitted must be in the specific brand and should be in the exact dosage formulation of the drug being bidd**

Proj. Ref. No. BAC1-2022-08-0051-B

End-User Property and Supply Division

Project Supply and Delivery of Drugs and Medicines - Tablet/Oral Solids

Opening of Bids: 16 September 2022

In cases where local laboratories are unavailable to perform drug assays, assays done abroad is accepted. The local COA is preferred and given more weight in the evaluation and awarding process.

**3.4. A notarized certificate** that it is the innovator drug (if applicable).

**3.5. Certificate of Good Manufacturing Process (CGMP).**

**3.6. Valid License to Operate (LTO).**

**3.7. A notarized certificate that the offered brand has not been subject to product complaint/product recall** for the past three (3) years.

**3.8. Certificate of Acceptance** from at least three (3) major hospitals issued within the year and should be supported with Sales Invoice (for new item/brand offered only).

**3.9. A notarized certificate** that there are sufficient stocks for the offered item/s for one (1) year.

**4.** The offered drug must conform to the latest Philippine Food and Drug Administration (FDA) Approved by:

**4.1. For all tablets and capsules**

**4.1.1. All tablets/capsules should be in foil or blister pack. A picture of the blister pack (front and back) should be submitted.**

**4.1.2.** Each individual flap in the tablet or capsule blister pack should be labeled with the generic name of the drug. **Dean VICENTE Y. BELIZARIO, JR., M.D.**

**4.1.3.** Dosage form and strength of the Active Pharmaceutical Ingredients (API) should appear on *Chairperson*

**4.1.4.** Name of drug, lot or batch number and expiry date must appear on every standard blister pack/foil strip and on the container or inner packaging. However, if the product is not restricted for dispensing in quantities less than the standard blister pack or foil strip, the batch or lot number and expiry date should appear on each unit.

**4.1.5.** Inner label must be the same as the outer label.

**4.1.6.** A complete drug literature/product insert must accompany the product.

**5.** The following must be complied with specific for **cytotoxic injectable drugs**.

**5.1. For cytotoxic injectable drugs, winning bidders are required to provide Material Safety Data Sheet (MSDS) and to submit Drug Profile** to the Pharmacy Department per company under the first Purchase Order.

**5.2. Winning bidders for cytotoxic injectable drugs are required to provide at least three (3) spill kits** per company under the first Purchase Order.

**6. New brands offered** shall be subject to further evaluation and shall require the following:

**6.1.** Validation of the submitted Certificate of Acceptance from at least three (3) major hospitals;

**6.2.** Justification from end-user/s to validate the acceptance of the good/s offered (to be facilitated by PGH-PSD).

**7. For the supply and delivery of awarded drugs and medicines.**

**7.1.** Delivery of the goods is required as stated in the request of the end-user, commencing on the 3rd working day of notification through confirmation fax/email that the approved Call-off/ Notice to Supplier (NTS) is already available for pick up.

**7.2.** Delivery schedule (whichever is applicable):

**7.2.1.** within seven (7) calendar days;

**7.2.2.** as may be called for;

**7.2.3.** staggered delivery within three (3) months

**\* 50% of the total quantity within seven (7) calendar days and 25% each for the succeeding months**

**Note: The end-user has the right to adjust the quantity to be delivered depending on the actual need of the hospital**

**7.3.** Deliveries shall have **at least two (2) years expiration date**.

**7.4.** Delivery of goods **with product complaint shall be put on hold** until receipt of the final decision of the PGH management whether to proceed with the acceptance or to cancel/return the items.

**7.5.** Delivered items found to be non-formulary at any given time shall be returned to the company and a credit memo shall be issued.

**7.6.** Stocks delivered are subject to random sampling for testing as to quality and conformity to label. Testing fee at supplier's expense.

**7.7.** Stocks with lot #/batch different from the submitted Certificate of Analysis (COA) will be subjected to testing as to quality and conformity to label. Testing fee at supplier's expense.

**Proj. Ref. No. BAC1-2022-08-0051-B**

**End-User Property and Supply Division**

**Project Supply and Delivery of Drugs and Medicines - Tablet/Oral Solids**

**Opening of Bids: 16 September 2022**

**7.8.** All items that had been pulled out for various reasons, a credit memo shall be issued by the Contractor within one (1) month, otherwise, a de shall be processed by UP Manila - PGH and the amount will be deducted from any amount due to Supplier.

**7.9.** It is understood that the Supplier is legally responsible to deliver all issued **CALL-OFF/s** (Purchase Order) and **failure to deliver the first** as scheduled shall mean automatic cancellation of the Call-Off and Notice to Execute Framework Agreement (NEFA). Purchase from other source fo shall be effected immediately to provide the requirements of the hospital. Penalty to the defaulting contractor shall be charged accordingly.

**8. Failure to comply with the submission of the required documents shall be ground for post-disqualification in accordance with RA 91**

**9.** Compliance with RA 9184 and other applicable laws.

Approved by:

**Dean CHARLOTTE M. CHIONG, MD, PhD**  
*Chairperson*

---

*(Signature over Printed Name of President/Gen. Manager)*

---

*(Name & Address of Company)*